The popularity of Sildenafil initially drove a boom for pharma, nevertheless recent developments present a uncertain picture for those considering a stake. Off-patent competitors are eroding earnings, and persistent https://zubairvzbj673159.blogsumer.com/40083454/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet